References
Key articles
World Health Organization. Guidelines for the treatment of human African trypanosomiasis. Jun 2024 [internet publication].Full text
Centers for Disease Control and Prevention. Clinical care of human African trypanosomiasis. Apr 2024 [internet publication].Full text
Reference articles
1. Büscher P, Cecchi G, Jamonneau V, et al. Human African trypanosomiasis. Lancet. 2017 Nov 25;390(10110):2397-409. Abstract
2. Franco JR, Cecchi G, Paone M, et al. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis. 2022 Jan;16(1):e0010047.Full text Abstract
3. World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense). December 2012 [internet publication].Full text
4. World Health Organization: The Global Health Observatory. Indicators: number of reported cases of human African trypanosomiasis (T.b. gambiense). 2024 [internet publication].Full text
5. World Health Organization: The Global Health Observatory. Indicators: number of new reported cases of human African trypanosomiasis (T.b. rhodesiense). 2024 [internet publication].Full text
6. Franco JR, Cecchi G, Priotto G, et al. Human African trypanosomiasis cases diagnosed in non-endemic countries (2011-2020). PLoS Negl Trop Dis. 2022 Nov;16(11):e0010885.Full text Abstract
7. Duggan AJ, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg. 1966 Jun;69(6):124-31. Abstract
8. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003 Mar 6;422(6927):83-7. Abstract
9. Truc P, Büscher P, Cuny G, et al. Atypical human infections by animal trypanosomes. PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2256.Full text Abstract
10. Kumar R, Gupta S, Bhutia WD, et al. Atypical human trypanosomosis: potentially emerging disease with lack of understanding. Zoonoses Public Health. 2022 Jun;69(4):259-76. Abstract
11. Herwaldt BL, Juranek DD. Laboratory-acquired malaria, leishmaniasis, trypanosomiasis, and toxoplasmosis. Am J Trop Med Hyg. 1993 Mar;48(3):313-23. Abstract
12. Rocha G, Martins A, Gama G, et al. Possible cases of sexual and congenital transmission of sleeping sickness. Lancet. 2004 Jan 17;363(9404):247. Abstract
13. Lindner AK, Priotto G. The unknown risk of vertical transmission in sleeping sickness - a literature review. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e783.Full text Abstract
14. Vickerman K. Developmental cycles and biology of pathogenic trypanosomes. Br Med Bull. 1985 Apr;41(2):105-14. Abstract
15. Pays E, Nolan DP. Expression and function of surface proteins in Trypanosoma brucei. Mol Biochem Parasitol. 1998 Mar 1;91(1):3-36. Abstract
16. Pays E. Antigenic variation in African trypanosomes. In: Dumas M, Bouteille B, Buguet A, eds. Progress in human African trypanosomiasis, sleeping sickness. Paris: Springer; 1999:31-52.
17. Lejon V, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis. 2003 May 1;187(9):1475-83. Abstract
18. Bisser S, Lejon V, Preux PM, et al. Blood-cerebrospinal fluid barrier and intrathecal immunoglobulins compared to field diagnosis of central nervous system involvement in sleeping sickness. J Neurol Sci. 2002 Jan 15;193(2):127-35. Abstract
19. Lejon V, Lardon J, Kenis G, et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg. 2002 May-Jun;96(3):329-33. Abstract
20. MacLean L, Odiit M, Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg. 2006 Mar;100(3):270-5. Abstract
21. Courtioux B, Pervieux L, Gedeao V, et al. Increased CXCL-13 levels in human African trypanosomiasis meningo-encephalitis. Trop Med Int Health. 2009 May;14(5):529-34. Abstract
22. Hainard A, Tiberti N, Robin X, et al. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis. 2009 Jun 16;3(6):e459.Full text Abstract
23. Sternberg J. Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol. 2004 Nov-Dec;26(11-12):469-76. Abstract
24. Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol. 2008 Aug;64(2):116-26. Abstract
25. Simarro PP, Cecchi G, Franco JR, et al. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis. 2012;6(10):e1859.Full text Abstract
26. Sholdt LL, Schreck CE, Mwangelwa MI, et al. Evaluations of permethrin-impregnated clothing and three topical repellent formulations of DEET against tsetse flies in Zambia. Med Vet Entomol. 1989 Apr;3(2):153-8. Abstract
27. Chappuis F, Stivanello E, Adams K, et al. Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in Southern Sudan. Am J Trop Med Hyg. 2004 Sep;71(3):313-7. Abstract
28. Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS Negl Trop Dis. 2011 Nov;5(11):e1358.Full text Abstract
29. Odiit M, Shaw A, Welburn SC, et al. Assessing the patterns of health-seeking behaviours and awareness among sleeping-sickness patients in eastern Uganda. Ann Trop Med Parasitol. 2004 Jun;98(4):339-48. Abstract
30. Bukachi SA, Wandibba S, Nyamongo IK. The treatment pathways followed by cases of human African trypanosomiasis in western Kenya and eastern Uganda. Ann Trop Med Parasitol. 2009 Apr;103(3):211-20. Abstract
31. Checchi F, Filipe JA, Haydon DT, et al. Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis. 2008 Feb 8;8:16.Full text Abstract
32. World Health Organization. Guidelines for the treatment of human African trypanosomiasis. Jun 2024 [internet publication].Full text
33. Odiit M, Kanshme F, Enyaru JCK. Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East Afr Med J. 1997 Dec;74(12):792-5. Abstract
34. Cottle LE, Peters JR, Hall A, et al. Multiorgan dysfunction caused by travel-associated African trypanosomiasis. Emerg Infect Dis. 2012 Feb;18(2):287-9.Full text Abstract
35. Chappuis F, Loutan L, Simarro P, et al. Options for the field diagnosis of human African trypanosomiasis. Clin Microbiol Rev. 2005 Jan;18(1):133-46.Full text Abstract
36. Greenwood BM, Whittle HC. The pathogenesis of sleeping sickness. Trans R Soc Trop Med Hyg. 1980;74(6):716-25. Abstract
37. Sullivan L, Wall SJ, Carrington M, et al. Proteomic selection of immunodiagnostic antigens for human African trypanosomiasis and generation of a prototype lateral flow immunodiagnostic device. PLoS Negl Trop Dis. 2013;7(2):e2087.Full text Abstract
38. Büscher P, Gilleman Q, Lejon V. Rapid diagnostic test for sleeping sickness. N Engl J Med. 2013 Mar 14;368(11):1069-70.Full text Abstract
39. Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health. 2014 Jun;2(6):e359-63.Full text Abstract
40. Bisser S, Lumbala C, Nguertoum E, et al. Sensitivity and specificity of a prototype rapid diagnostic test for the detection of Trypanosoma brucei gambiense infection: a multi-centric prospective study. PLoS Negl Trop Dis. 2016 Apr 8;10(4):e0004608.Full text Abstract
41. Miezan TW, Meda AH, Doua F, et al. Evaluation of the parasitologic techniques used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in the Ivory Coast [in French]. Bull Soc Pathol Exot. 1994;87(2):101-4. Abstract
42. Lutumba P, Robays J, Miaka C, et al. Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness [in French]. Trop Med Int Health. 2006 Apr;11(4):470-8. Abstract
43. Camara M, Camara O, Ilboudo H, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test. Trop Med Int Health. 2010 Jul;15(7):796-9.Full text Abstract
44. Mumba Ngoyi D, Ali Ekangu R, Mumvemba Kodi MF, et al. Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness. PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2954.Full text Abstract
45. Simarro PP, Ruiz JA, Franco JR, et al. Attitude towards CATT-positive individuals without parasitological conformation in the African trypanosomiasis (T b gambiense) focus of Quiçama (Angola). Trop Med Int Health. 1999 Dec;4(12):858-61.Full text Abstract
46. Inojosa WO, Augusto I, Bisoffi Z, et al. Diagnosing human African trypanosomiasis in Angola using card agglutination test: observational study of active and passive case finding strategies. BMJ. 2006 Jun 24;332(7556):1479.Full text Abstract
47. Kager PA, Schipper HG, Stam J, et al. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature. Am J Trop Med Hyg. 2009 Jun;80(6):947-52. Abstract
48. Boukobza M, Lariven S, Houzé S, et al. Unusual MRI findings in African Trypanosoma brucei gambiense trypanosomiasis: dentate nuclei and hypothalamic lesions. Am J Trop Med Hyg. 2020 Jan;102(1):5-6.Full text Abstract
49. Van Meirvenne N, Magnus E, Büscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop. 1995 Dec;60(3):189-99. Abstract
50. Jamonneau V, Bucheton B, Kaboré J, et al. Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e917.Full text Abstract
51. Tiberti N, Hainard A, Lejon V, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One. 2012;7:e40909.Full text Abstract
52. Amin DN, Mumba Ngoyi D, Nhkwachi GM, et al. Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg. 2010 Jun;82(6):983-90.Full text Abstract
53. Tiberti N, Lejon V, Hainard A, et al. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2013;7(2):e2088.Full text Abstract
54. Ngay Lukusa I, Van Reet N, Mumba Ngoyi D, et al. Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection. PLoS Negl Trop Dis. 2021 Sep;15(9):e0009739.Full text Abstract
55. Ilboudo H, Camara O, Ravel S, et al. Trypanosoma brucei gambiense spliced leader RNA is a more specific marker for cure of human African trypanosomiasis than T. b. gambiense DNA. J Infect Dis. 2015 Dec 15;212(12):1996-8.Full text Abstract
56. González-Andrade P, Camara M, Ilboudo H, et al. Diagnosis of trypanosomatid infections: targeting the spliced leader RNA. J Mol Diagn. 2014 Jul;16(4):400-4.Full text Abstract
57. Buguet A, Bourdon L, Bouteille B, et al. The duality of sleeping sickness: focusing on sleep. Sleep Med Rev. 2001 Apr;5(2):139-53. Abstract
58. Simon F, Mura M, Pagès F, et al. Urban transmission of human African trypanosomiasis, Gabon. Emerg Infect Dis. 2012 Jan;18(1):165-7.Full text Abstract
59. Blum JA, Zellweger MJ, Burri C, et al. Cardiac involvement in African and American trypanosomiasis. Lancet Infect Dis. 2008 Oct;8(10):631-41. Abstract
60. Blum JA, Schmid C, Burri C, et al. Cardiac alterations in human African trypanosomiasis (T b gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis. 2009;3(2):e383.Full text Abstract
61. Whittle HC, Greenwood BM, Bidwell DE, et al. IgM and antibody measurement in the diagnosis and management of Gambian trypanosomiasis. Am J Trop Med Hyg. 1977 Nov;26(6 Pt 1):1129-34. Abstract
62. Lambert PH, Berney M, Kazyumba G. Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis: correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis. J Clin Invest. 1981 Jan;67(1):77-85.Full text Abstract
63. Wellde BT, Chumo DA, Reardon MJ, et al. Presenting features of Rhodesian sleeping sickness patients in the Lambwe Valley, Kenya. Ann Trop Med Parasitol. 1989 Aug;83 Suppl 1:73-89. Abstract
64. Bisser S, Bouteille B, Sarda J, et al. Contribution of biochemical tests in the diagnosis of the nervous phase of human African trypanosomiasis [in French]. Bull Soc Pathol Exot. 1997;90(5):321-6. Abstract
65. Apted FIC. Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW, ed. The African trypanosomiases. London: George Allen and Unwin Ltd; 1970:661-83.
66. Jamonneau V, Camara O, Ilboudo H, et al. Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. PLoS Negl Trop Dis. 2015 Feb 2;9(2):e0003480.Full text Abstract
67. Koné M, Kaba D, Kaboré J, et al. Passive surveillance of human African trypanosomiasis in Côte d'Ivoire: understanding prevalence, clinical symptoms and signs, and diagnostic test characteristics. PLoS Negl Trop Dis. 2021 Aug;15(8):e0009656.Full text Abstract
68. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. b. gambiense trypanosomiasis. Ann Soc Belg Med Trop. 1978;58(3):169-76. Abstract
69. Dukes P, Gibson WC, Gashumba JK, et al. Absence of the LiTat 1.3 (CATT antigen) gene in Trypanosoma brucei gambiense stocks from Cameroon. Acta Trop. 1992 Jun;51(2):123-34. Abstract
70. Paquet C, Ancelle T, Gastellu-Etchegorry M, et al. Persistence of antibodies to Trypanosoma brucei gambiense after treatment of human trypanosomiasis in Uganda. Lancet. 1992 Jul 25;340(8813):250. Abstract
71. Miezan TW, Dje NN, Doua F, et al. Human African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast) [in French]. Bull Soc Pathol Exot. 2002 Dec;95(5):362-5. Abstract
72. Lejon V, Ngoyi DM, Boelaert M, et al. A CATT negative result after treatment for human African trypanosomiasis is no indication for cure. PLoS Negl Trop Dis. 2010 Jan 26;4(1):e590.Full text Abstract
73. Simarro PP, Franco JR, Ndongo P. Field evaluation of several serological screening tests for sleeping sickness (T b gambiense). Bull Liais Doc OCEAC. 1999;32:28-33.
74. Kegels G, Criel B, van Lerberghe W, et al. Screening for Trypanosoma brucei gambiense antibodies with the indirect fluorescent antibody test (IFAT). Ann Soc Belg Med Trop. 1992 Dec;72(4):271-81. Abstract
75. Dukes P, Rickman LR, Killick-Kendrick R, et al. A field comparison of seven diagnostic techniques for human trypanosomiasis in the Luangwa Valley, Zambia. Tropenmed Parasitol. 1984 Sep;35(3):141-7. Abstract
76. Wellde BT, Chumo DA, Reardon MJ, et al. Diagnosis of Rhodesian sleeping sickness in the Lambwe Valley (1980-1984). Ann Trop Med Parasitol. 1989 Aug;83 Suppl 1:63-71. Abstract
77. Bailey NM, Cunningham MP, Kimber CD. The indirect fluorescent antibody technique applied to dried blood, for use as a screening test in the diagnosis of human trypanosomiasis in Africa. Trans R Soc Trop Med Hyg. 1967;61(5):696-700. Abstract
78. Roffi J, Carrie J, Garre MT, et al. Immunoenzymatic detection of human African trypanosomiasis using dried blood samples [in French]. Bull Soc Pathol Exot. 1980 Jan-Feb;73(1):67-74. Abstract
79. Vervoort T, Magnus E, Van Meirvenne N. Enzyme-linked immunosorbent assay (ELISA) with variable antigen for serodiagnosis of T b gambiense trypanosomiasis. Ann Soc Belg Med Trop. 1978;58(3):177-83. Abstract
80. Mangenot M, Chaize J, Desfontaine M, et al. Comparative value of ELISA technique and immunofluorescence for the detection in the foci of human African trypanosomiasis [in French]. Med Trop. 1979 Sep-Oct;39(5):527-30. Abstract
81. Lejon V, Jamonneau V, Solano P, et al. Detection of trypanosome-specific antibodies in saliva, towards non-invasive serological diagnosis of sleeping sickness. Trop Med Int Health. 2006 May;11(5):620-7.Full text Abstract
82. Woo PT. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop. 1970;27(4):384-6. Abstract
83. Bailey JW, Smith DH. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):630. Abstract
84. Truc P, Bailey JW, Doua F, et al. A comparison of parasitological methods for the diagnosis of Gambian trypanosomiasis in an area of low endemicity in Côte d'Ivoire. Trans R Soc Trop Med Hyg. 1994 Jul-Aug;88(4):419-21. Abstract
85. Büscher P, Mumba Ngoyi D, Kaboré J, et al. Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis. 2009 Nov 24;3(11):e471.Full text Abstract
86. Lumsden WH, Kimber CD, Evans DA, et al. Trypanosoma brucei: miniature anion-exchange centrifugation technique for detection of low parasitaemias: adaptation for field use. Trans R Soc Trop Med Hyg. 1979;73(3):312-7. Abstract
87. Boda C, Courtioux B, Roques P, et al. Immunophenotypic lymphocyte profiles in human African trypanosomiasis. PLOS One. 2009 Jul 8;4(7):e6184.Full text Abstract
88. Cattand P, Miézan BT, de Raadt P. Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull World Health Organ. 1988;66(1):83-6.Full text Abstract
89. Miezan TW, Meda AH, Doua F, et al. Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes. Trans R Soc Trop Med Hyg. 2000 May-Jun;94(3):293. Abstract
90. Mumba Ngoyi D, Menten J, Pyana PP, et al. Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques. Trop Med Int Health. 2013 Jun;18(6):778-82.Full text Abstract
91. Lejon V, Büscher P. Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health. 2005 May;10(5):395-403.Full text Abstract
92. Moser DR, Cook GA, Ochs DE, et al. Detection of Trypanosoma congolense and Trypanosoma brucei subspecies by DNA amplification using the polymerase chain reaction. Parasitology. 1989 Aug;99 Pt 1:57-66. Abstract
93. Becker S, Franco JR, Simarro PP, et al. Real-time PCR for detection of Trypanosoma brucei in human blood samples. Diagn Microbiol Infect Dis. 2004 Nov;50(3):193-9. Abstract
94. Kabiri M, Franco JR, Simarro PP, et al. Detection of Trypanosoma brucei gambiense in sleeping sickness suspects by PCR amplification of expression-site-associated genes 6 and 7. Trop Med Int Health. 1999 Oct;4(10):658-61.Full text Abstract
95. Deborggraeve S, Claes F, Laurent T, et al. Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol. 2006 Aug;44(8):2884-9.Full text Abstract
96. Radwanska M, Chamekh M, Vanhamme L, et al. The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg. 2002 Dec;67(6):684-90. Abstract
97. Welburn SC, Picozzi K, Fevre EM, et al. Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet. 2001 Dec 15;358(9298):2017-9. Abstract
98. Picozzi K, Fèvre EM, Odiit M, et al. Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ. 2005 Nov 26;331(7527):1238.Full text Abstract
99. Radwanska M, Claes F, Magez S, et al. Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense. Am J Trop Med Hyg. 2002 Sep;67(3):289-95. Abstract
100. Jamonneau V, Solano P, Garcia A, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. Trop Med Int Health. 2003 Jul;8(7):589-94.Full text Abstract
101. Kirchhoff LV. Use of a PCR assay for diagnosing African trypanosomiasis of the CNS: a case report. Cent Afr J Med. 1998 May;44(5):134-6. Abstract
102. Truc P, Jamonneau V, Cuny G, et al. Use of polymerase chain reaction in human African trypanosomiasis stage determination and follow-up. Bull World Health Organ. 1999;77(9):745-8.Full text Abstract
103. Deborggraeve S, Lejon V, Ekangu RA, et al. Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. PLoS Negl Trop Dis. 2011 Feb 22;5(2):e972.Full text Abstract
104. Kuboki N, Inoue N, Sakurai T, et al. Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol. 2003 Dec;41(12):5517-24.Full text Abstract
105. Njiru ZK, Traub R, Ouma JO, et al. Detection of group 1 Trypanosoma brucei gambiense by loop-mediated isothermal amplification. J Clin Microbiol. 2011 Apr;49(4):1530-6.Full text Abstract
106. Wastling SL, Picozzi K, Kakembo AS, et al. LAMP for human African trypanosomiasis: a comparative study of detection formats. PLoS Negl Trop Dis. 2010 Nov 2;4(11):e865.Full text Abstract
107. Mugasa CM, Adams ER, Boer KR, et al. Diagnostic accuracy of molecular amplification tests for human African trypanosomiasis - systematic review. PLoS Negl Trop Dis. 2012 Jan;6(1):e1438.Full text Abstract
108. Deborggraeve S, Büscher P. Molecular diagnostics for sleeping sickness: what is the benefit for the patient? Lancet Infect Dis. 2010 Jun;10(6):433-9. Abstract
109. Deborggraeve S, Büscher P. Recent progress in molecular diagnosis of sleeping sickness. Expert Rev Mol Diagn. 2012 Sep;12(7):719-30. Abstract
110. Mitashi P, Hasker E, Mumba Ngoyi D, et al. Diagnostic accuracy of Loopamp Trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples. PLos Negl Trop Dis. 2013 Oct 17;7(10):e2504.Full text Abstract
111. Lejon V, Sindic C, Van Antwerpen MP, et al. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response. Eur J Neurol. 2003 Nov;10(6):711-9. Abstract
112. Geerts M, Van Reet N, Leyten S, et al. Trypanosoma brucei gambiense-iELISA: a promising new test for the post-elimination monitoring of human African trypanosomiasis. Clin Infect Dis. 2021 Nov 2;73(9):e2477-83.Full text Abstract
113. Gillet P, Mumba Ngoyi D, Lukuka A, et al. False positivity of non-targeted infections in malaria rapid diagnostic tests: the case of human African trypanosomiasis. PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2180.Full text Abstract
114. Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008 Mar 29;336(7646):705.Full text Abstract
115. Lejon V, Ngoyi DM, Ilunga M, et al. Low specificities of HIV diagnostic tests caused by Trypanosoma brucei gambiense sleeping sickness. J Clin Microbiol. 2010 Aug;48(8):2836-9. Abstract
116. Sahlas DJ, MacLean JD, Janevski J, et al. Clinical problem-solving: out of Africa. N Engl J Med. 2002 Sep 5;347(10):749-53. Abstract
117. Sindato C, Kibona SN, Nkya GM, et al. Challenges in the diagnosis and management of sleeping sickness: a case report. Tanzania J Health Res. 2008 Jul;10(3):177-81. Abstract
118. Louis FJ, Kohange Tongue L, Ebo'O Eyenga V, et al. Organizing an active screening campaign for human African trypanosomiasis due to Trypanosoma brucei gambiense [in French]. Med Trop. 2008 Feb;68(1):11-6. Abstract
119. Checchi F, Chappuis F, Karunakara U, et al. Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jul;5(7):e1233.Full text Abstract
120. Van Nieuwenhove S, Kande Betu-Ku-Mesu V, Mansinsa Diabakana P, et al. Sleeping sickness resurgence in the DRC: the past decade. Trop Med Int Health. 2001 May;6(5):335-41.Full text Abstract
121. World Health Organization. WHO outlines criteria to assess elimination of sleeping sickness. Jul 2018 [internet publication].Full text
122. World Health Organization. Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021-2030. Sep 2022 [internet publication].Full text
123. Centers for Disease Control and Prevention. Clinical guidance for human African trypanosomiasis. Mar 2024 [internet publication].Full text
124. Centers for Disease Control and Prevention. CDC yellow book 2024: trypanosomiasis, African. May 2023 [internet publication].Full text
125. Centers for Disease Control and Prevention. Clinical care of human African trypanosomiasis. Apr 2024 [internet publication].Full text
126. World Health Organization. WHO model prescribing information: drugs used in parasitic diseases, 2nd edition. Geneva: World Health Organization, 1995.Full text
127. Tweats D, Bourdin Trunz B, Torreele E. Genotoxicity profile of fexinidazole - a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis. 2012 Sep;27(5):523-32. Abstract
128. Stauffert I, Paulini H, Steinmann U, et al. Investigations on mutagenicity and genotoxicity of pentamidine and some related trypanocidal diamidines. Mutation Research. 1990 Oct;245(2):93-8. Abstract
129. Kirchner DL, Mercieca MD, Crowell JA, et al. Developmental toxicity studies of 2-(difluoromethyl)-dl-ornithine (DFMO) in rats and rabbits. Toxicol Sci. 1999 Jul;50(1):127-35. Abstract
130. Freeman SJ, Lloyd JB. Evidence that suramin and aurothiomalate are teratogenic in rat by disturbing yolk sac-mediated embryonic protein nutrition. Chem Biol Interact. 1986 May;58(2):149-60. Abstract
131. Reinhardt MC, MacLeod CL. African trypanosomiasis (African sleeping sickness). In: MacLeod CL, ed. Parasitic infections in pregnancy and the newborn. Oxford: Oxford University Press; 1988:1-308.
132. Kande Betu Ku Mesu V, Mutombo Kalonji W, Bardonneau C, et al. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021 Jul;9(7):e999-1008.Full text Abstract
133. Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018 Jan 13;391(10116):144-54. Abstract
134. Lutje V, Probyn K, Seixas J, et al. Chemotherapy for second-stage human African trypanosomiasis: drugs in use. Cochrane Database Syst Rev. 2021 Dec 9;(12):CD015374.Full text Abstract
135. Doua F, Miezan TW, Sanon Singaro JR, et al. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg. 1996 Dec;55(6):586-8. Abstract
136. Balasegaram M, Harris S, Checchi F, et al. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull World Health Organ. 2006 Oct;84(10):777-82. Abstract
137. Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis. 2005 Sep 1;41(5):748-51. Abstract
138. Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (Impamel II). J Infect Dis. 2005 Jun 1;191(11):1922-31. Abstract
139. Kuepfer I, Schmid C, Allan M, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012 Aug;6(8):e1695.Full text Abstract
140. Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 1994;33:1-47. Abstract
141. Barrett MP, Boykin DW, Brun R, et al. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2007 Dec;152(8):1155-71.Full text Abstract
142. Delespaux V, de Koning HP. Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat. 2007 Feb-Apr;10(1-2):30-50. Abstract
143. Milord F, Pepin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992 Sep 12;340(8820):652-5. Abstract
144. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health. 2001 May;6(5):390-400.Full text Abstract
145. Chappuis F. Eflornithine for the treatment of human African trypanosomiasis; practical perspectives [in French]. Dev Sante. 2004 Jun;171:41-7.
146. Eperon G, Balasegaram M, Potet J, et al. Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther. 2014 Nov;12(11):1407-17.Full text Abstract
147. Jacobs RT, Plattner JJ, Nare B, et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem. 2011 Aug;3(10):1259-78. Abstract
148. Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jun;5(6):e1151.Full text Abstract
149. Dickie EA, Giordani F, Gould MK, et al. New drugs for human African trypanosomiasis: a twenty first century success story. Trop Med Infect Dis. 2020 Feb 19;5(1):29.Full text Abstract
150. Checchi F, Filipe JA, Barrett MP, et al. The natural progression of gambiense sleeping sickness: what is the evidence? PLoS Negl Trop Dis. 2008;2(12):e303.Full text Abstract
151. Jamonneau V, Ilboudo H, Kaboré J, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis. 2012;6(6):e1691.Full text Abstract
152. Bucheton B, MacLeod A, Jamonneau V. Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol. 2011 Aug;33(8):438-47. Abstract
153. Robays J, Nyamowala G, Sese C, et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis. 2008 Jun;14(6):966-7.Full text Abstract
154. Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):439-42. Abstract
155. World Health Organization. Epidemiology and control of African trypanosomiasis. WHO Technical Report Series 739. 1986 [internet publication].Full text
156. World Health Organization. Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis. Geneva: WHO; 2007.Full text
157. Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage Gambiense human African trypanosomiasis: Médecins sans Frontières experience in the Democratic Republic of the Congo. Clin Infect Dis. 2013 Jan;56(2):195-203. Abstract
158. Franco JR, Simarro PP, Diarra A, et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med. 2012 Aug 23;3:93-101.Full text Abstract
159. Fèvre EM, Coleman PG, Welburn SC, et al. Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda. Emerg Infect Dis. 2004 Apr;10(4):567-73.Full text Abstract
160. Fairlamb AH. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003 Nov;19(11):488-94. Abstract
161. Mudji J, Blum A, Grize L, et al. Gambiense human African trypanosomiasis sequelae after treatment: a follow-up study 12 years after treatment. Trop Med Infect Dis. 2020 Jan 11;5(1):10.Full text Abstract
162. Priotto G, Chappuis F, Bastard M, et al. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis. PLoS Negl Trop Dis. 2012;6(6):e1662.Full text Abstract
163. Mumba Ngoyi D, Lejon V, Pyana P, et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2010 Feb 1;201(3):453-63. Abstract
Use of this content is subject to our disclaimer